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Liposomes have been long considered as a vaccine delivery system but this technology
remains to be fully utilized. Here, we describe a novel liposome-based subunit
vaccine formulation for tuberculosis (TB) based on phosphatidylserine encapsulating
two prominent TB antigens, Ag85B, and ESAT-6. We show that the resulting liposomes
(Lipo-AE) are stable upon storage and can be readily taken up by antigen presenting
cells and that their antigenic cargo is delivered and processed within endosomal cell
compartments. The Lipo-AE vaccine formulation combined with the PolyIC adjuvant
induced a mixed Th1/Th17-Th2 immune response to Ag85B but only a weak response
to ESAT-6. An immunization regimen based on systemic delivery followed by mucosal
boost with Lipo-AE resulted in the accumulation of resident memory T cells in the
lungs. Most importantly though, when Lipo-AE vaccine candidate was administered to
BCG-immunized mice subsequently challenged with low dose aerosol Mycobacterium
tuberculosis, we observed a significant reduction of the bacterial load in the lungs and
spleen compared to BCG alone. We therefore conclude that the immunization with
mycobacterial antigens delivered by phosphatidylserine based liposomes in combination
with Poly:IC adjuvant may represent a novel BCG boosting vaccination strategy.
Keywords: liposomes, tuberculosis, vaccine, BCG, immunity
INTRODUCTION
Despite the availability of a vaccine and drug regimens, tuberculosis (TB) remains a major health
burden globally. In 2016, there were∼1.3million deaths fromTB amongHIV-negative and 374,000
among HIV-positive individuals, making it the 9th cause of death worldwide and the number one
due to a single infectious agent (1).
The current vaccine, Bacille Calmette Guérin (BCG), was first administered nearly 100 years
ago and is still extensively used today. BCG was first used in children in 1921 and is now given to
more than 120 million people worldwide every year, with 4 billion people already immunized (2).
It is effective at preventing severe forms of TB in children but provides varying levels of protection
against pulmonary TB in adults. Revaccination with BCG has not been shown to be advantageous
(3, 4) and is not recommended by the WHO. Coupled with the emergence of multi-drug resistant
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tuberculosis (MDR-TB) with unsatisfactory treatment rates,
it is clear that a more effective TB vaccine is a major
healthcare priority.
Although there are several vaccine candidates at various stages
of clinical trials and many more at preclinical stage of research
and development, it is important to continuously feed the TB
vaccine pipeline with both live and subunit vaccines. This is
because it may well be that more than a single vaccination
strategy will be needed to protect different human populations
against TB (e.g., different age groups, HIV status, geographical
location etc.). For example, a replacement BCG vaccine is likely
to be another live attenuated organism (recombinant BCG or
attenuated Mtb) in order to protect young children from severe
primary TB infection but a subunit vaccine may be preferable in
HIV-positive population due to the host’s immunocompromised
state. Likewise, it may be preferable to boost BCG with a subunit
rather than another attenuated vaccine to avoid excessive delayed
hypersensitivity reactions (Koch’s phenomenon). Recombinant
protein subunit vaccines are inherently safer but are often weakly
immunogenic and require adjuvants and/or specialized delivery
systems to induce protective immunity.
One such delivery system is liposomes, which were identified
as a potential drug delivery platform in the 1970s. However, the
discovery that liposomes preferentially target tissue macrophages
(5) highlighted their potential also as a vaccine delivery system
(6, 7). Subsequently, they have been used in the context
of both bacterial (8, 9) and viral infections (10) and even
in cancer immunotherapies (11). An attractive characteristic
of the liposomal delivery platforms is that they can shelter
antigens from degradation, promote phagocytosis by antigen-
presenting cells (APCs) (7) and induce phagosome-cytosol cross-
presentation pathway of antigenic peptides on MHC Class I
molecules (12, 13).
The apoptotic body-like liposomes (ABLs, Figure 1A) used
in the present study are prepared from phosphatidylserine (PS),
rendering them similar to apoptotic bodies. PS is hydrophilic and
appears on the surface of early apoptotic cells (14); this “flags up”
the dying cells as a target for APCs such as macrophages and
dendritic cells (DC) (15, 16). It is thought that this phenomenon
can augment the presentation of the antigens by APCs, leading to
improved T cell responses (17). As a cell initiates apoptosis, the
PS normally situated on the inner face of the lipid bilayer of the
cell membrane is exposed (14). PS is implicated in the detection
of apoptotic cells by its interaction with Tim4 and Tim1 on APC,
which facilitates phagocytosis (18).
We therefore hypothesized that the PS associated antigens will
similarly be taken up by professional APCs resulting in their
cross-presentation and amplification of the immune response.
Here, we present the evidence for the utility of this vaccine
delivery system by demonstration that liposomally encapsulated
Mtb antigens can enhance BCG-afforded protection against
tuberculosis infection in mice.
MATERIALS AND METHODS
Generation of PS Liposomes
Briefly, the inner monolayer lipid was prepared by suspending
phosphatidylserine (PS, Avanti Polar Lipids) in 1ml of anhydrous
dodecane at the concentration of 0.2 mg/ml, sonication for
30min and overnight incubation. The following day, 10 µg
of Ag85B, or ESAT-6 (Lionex Diagnostics and Therapeutics),
or bovine serum albumin conjugated to Alexafluor488 (AF488-
BSA), Alexafluor647 (AF647) (Molecular Probes) or ovalbumin
conjugated to BODIPY R© FL [500µg/ml] (DQ-OVA), were
added to inner monolayer lipid suspension and sonicated until
a homogeneous solution was obtained. The inner monolayer
lipid for empty control liposomes was prepared using the
same buffer used to suspend the respective antigen. The
outer lipid monolayer was prepared by suspending PS in 99:1
dodecane: silicone solution to get a lipid concentration of 0.05
mg/ml. Thereafter, 2ml of outer monolayer lipid suspension
was added to 3ml of 0.9% NaCl solution. Finally, the inner
monolayer lipid suspension was added to 2ml lipid phase
and the sample was centrifuged at 120 × g for 10min. After
the centrifugation, liposomes were collected in the aqueous
phase using a 5ml syringe with a 16-gauge stainless steel
needle. Liposomes were quantified and characterized in terms
of dimensions as described (19). To determine antigen recovery
following encapsulation, liposomes were dialysed against a
100 kDa membrane (Float-A-Lyzer R© G2, Spectrum Labs),
according to manufacturer’s instructions. Encapsulated antigen
was then quantified by CBQCA Protein Quantitation Kit (C-
6667Molecular Probes) according to manufacturer’s instructions
by fluorimetric analysis (Thermofisher VARIOSKAN LUX). The
schematic representation of liposomes with encapsulated antigen
is shown in Figure 1A. For the final vaccine formulation, equal
numbers of Ag85B and ESAT-6 encapsulating liposomes were
combined to generate the Lipo-AE vaccine candidate.
Generation of Human DC
Human bloodmonocytes from healthy volunteers were separated
from peripheral blood mononuclear cells (PBMCs), by using
anti-CD14 monoclonal antibodies conjugated to magnetic
microbeads (Miltenyi Biotec), according to manufacturer’s
instructions. To obtain immature dendritic cells (iDc),
cells were suspended in complete medium (RPMI 1640
supplemented with 10% fetal bovine serum, 2mM L-Glutamine
and 5µg/ml Gentamicin) and incubated for 5 days in 24-
well plates at the concentration of 5 × 105 cells/well in the
presence of 20 ng/mL GM-CSF (Sigma-Aldrich) and 20 ng/mL
IL-4 (Miltenyi Biotec). To obtain mature dendritic cells
(mDC), iDCs were further stimulated for 18 h with 100 ng/ml
lipopolysaccharides (Sigma-Aldrich).
Flow Cytometry Analysis of Stability and
Antigen Delivery by PS Liposomes
The stability of PS liposomes loaded with AF488-BSA was
assessed in terms of fluorescence intensity immediately and at 30
days after their preparation by flow cytometry analysis. Antigen
internalization was analyzed after incubation of immature
(iDC) or mature DC (mDC) with PS liposomes loaded with
bovine serum albumin conjugated to Alexafluor647 (BSA-
AF647) (Molecular Probes), at the ratio liposome: cell of 5:1,
for 1 h at 37◦C. Antigen processing was evaluated in iDC
after exposure to ovalbumin conjugated to BODIPY R© FL (DQ-
OVA), a self-quenched conjugate that exhibits bright green
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FIGURE 1 | Encapsulation and stability of PS/PS liposomes and their physical characteristics. The stability of PS liposomes carrying Alexafluor488-BSA
was assessed for fluorescence intensity by flow cytometry and size distribution by Malverin Zetasizer, immediately and after 30 days from liposome generation and
storage at 4◦C. (A) Schematic showing PS/PS liposome encapsulating an antigen. (B) Overlay of flow cytometry histogram plots of AF488-BSA loaded liposomes
with “empty” liposomes over time. Gray corresponds to empty liposomes while green corresponds to AF488-BSA liposomes after 30 days storage at 4◦C. (C) Size
distribution measured by Zetasizer of Ag85B-loaded liposomes following 30 day storage at 4◦C.
fluorescence upon proteolytic processing and red fluorescence
upon accumulation of proteolysed fragments in endosomal
compartments. The analyses were performed by a FACSCalibur
flow cytometer (Becton Dickinson).
Confocal Microscopy Analysis of Antigen
Processing in Dendritic Cells
Briefly, iDC were stained with the nucleic acid stain Hoechst
(Molecular Probes) and the acidophilic dye Lysotraker Red
(Molecular Probes) for 15min at 37◦C. Thereafter, cells were
washed with PBS, and exposed to PS liposomes loaded with
AF488-BSA at the ratio 5:1 (liposome:cell) for 90min at 37◦C.
The analysis was performed by a confocal laser scanning
microscope IX 81 and OLYMPUS FV1000 operating system.
Animals
All animals were used with approval from St. George’s University
of London Ethics Committee under an approved UK Home
Office animal project license and used in accordance with the
Animals (Scientific Procedures) Act 1986. 8–10 weeks old female
C57BL/6 mice were used for this study and were obtained from
Charles River, UK. Animal work was conducted at St. George’s
University of London Biological Research Facility in accordance
with local guidelines, including approval from the St. George’s
University of London Research Ethics Committee and national
legislation, the Animals in Scientific Procedures Act, 1986. All
procedures were performed under the approved UKHomeOffice
animal project license.
Recombinant Proteins
Ag85B and ESAT-6 antigens of Mtb were produced in E.
coli by Lionex company (Braunschweig, Germany) using the
standard cloning techniques and the IPTG-inducible expression
vector pLEXWO481. Recombinant proteins were isolated from
inclusion bodies after denaturation in 8M urea using metal
chelate chromatography (Ni-NTA Superflow, Qiagen) and
subsequent refolding by dialysis. Purity was assessed by SDS-
PAGE (>97% purity) and identity confirmed by Western blots
specific for antigens. Endotoxin content was measured by LAL
assay and determined to be <5 I.U./mg.
Immunizations
Mice were first immunized subcutaneously at the base of the tail
with 5 × 105 CFU BCG Pasteur in 0.1ml or a matched volume
of phosphate saline solution (Sigma) as a control. Ten weeks
later, mice received 0.1ml of Lipo-AE formulation (containing
∼106 liposomes, 1 µg of Ag85B and 0.2 µg ESAT-6) also by s.c.
injection at the base of the tail and then 3 weeks later a further
intranasal inoculation of 0.05ml of the same formulation, while
under light anesthesia. All Lipo-AE immunizations included 20
µg/per dose of poly(I:C) as the adjuvant. Further details of the
dosing regimen are given in the corresponding figure legends.
Low-Dose Aerosol Mtb Infection and
Bacterial Enumeration
Mice were infected 4 weeks after the final immunization by
aerosol with Mtb (H37Rv strain) at a low dose of ∼200 bacilli
per animal. The dose was delivered by nose only exposure using
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the Biaera aerosol generator controlled by the AeroMP software
(Biaera Technologies) and housed in a dedicated Containment
Level 3 (CL3) laboratory at Biological Research facilities at St.
George’s. Mice were left infected for 4 weeks before culling and
bacterial enumeration in the lungs and spleens. The organs were
homogenized in 3ml of 0.1% Triton x-100 using the Precellys
equipment. Serial dilutions of the homogenate were prepared
and plated onMiddlebrook 7H11 plates supplemented by OADC
(Becton Dickinson) and bacterial colonies counted 3 weeks later.
The pathogenic Mtb in vitro work was performed in the CL3TB
suite at the Institute for Infection and Immunity at St. George’s.
Mucosal Antibody Responses
IgG and IgA in bronchoalveolar lavage (BAL) specific for antigens
was measured by ELISA. Antigens (Ag85B or ESAT-6, Lionex)
at 2µg/ml were used to coat the wells of an ELISA plate.
After washing with PBS 0.05% v/v Tween-20 and blocking
with PBS 1% w/v BSA, 0.05% v/v Tween-20, samples were
added in 3-fold dilutions. Specific IgG and IgA were detected
with alkaline phosphatase conjugated anti-mouse IgG (Jackson
Immunoresearch) and anti-mouse IgA (Sigma), respectively,
and the substrate SigmaFast p-nitrophenyl phosphate (Sigma).
Triplicate assays were read at 450 nm on a Tecan200 plate
reader and data plotted as relative antibody titers as described
in Hart et al. (20).
T Cell Proliferation, Cytokine Production,
and Lung Trm
T cell proliferation was assessed by measuring the incorporation
of radio-labeled thymidine [3H] after stimulation of splenocytes
with recall antigens. Erythrocyte-depleted splenocytes were
seeded at 1.5 × 105/well in complete RPMI 1640 medium
supplemented with 10% FBS and stimulated with 5µg/ml antigen
or 1 µg.ml ConA as the positive control. After 48 h incubation,
1 µiCi of 3H-thymidine (PerkinElmer, Wallac, UK) was added
before a further 24 h incubation. Cells were harvested with
the Harvester 96 (TomTec Life Sciences, Hamdem, USA) onto
Printed Filtermat paper (PerkinElmer) prior to the addition
of melted wax (MeltiLex TM A. PerkinElmer) onto each
scintillation sheet. Radioactive counts per minute (cpm) were
measured using the 1,450 Microbeta Plus-Liquid Scintillation
Counter (PerkinElmer).
For phenotypic analysis of proliferating T cells, splenocytes
were stimulated with 5µg/mL Ag85B or 1µg/mL α-CD3
(Biolegend) for 5 days, followed by surface staining with CD4-
PerCP/Cy5.5, CD8-Brilliant Violet 510, CD44-FITC, CD62L-
PE, and CD90.2-Brilliant Violet 421—all from Biolegend. Cells
were then fixed and permeabilized using the eBioscience
Foxp3/Transcription Factor Staining Buffer Set and stained
with Ki67-APC. Example of gating strategy is shown in
Supplemental Figure S1.
Culture supernatant cytokine levels were measured using
the mouse LegendPlexTM kit (Biolegend) according to the
manufacturer’s instructions. Samples were acquired on a BD
FACSCalibur, and data analyzed using the proprietary data
analysis software (Biolegend).
For detection of lung resident memory T cells (Trm), lungs
were perfused of blood by flushing PBS through the right
ventricle. Tissue was then dissected into 1mm pieces using a
scalpel, followed by digestion in 1 mg/mL collagenase and 0.5
mg/mLDNase I (Roche). Cells were then passed through a 70µm
strainer (Becton Dickinson), contaminating erythrocytes were
lysed, and mononuclear cells were stained for CD3-APC, CD4-
PerCP/Cy5.5, CD8-Brilliant Violet 510, CD44-FITC, CD62L-
PE, CD69-PE/Cy7, and CD103-Brilliant Violet 421—all from
Biolegend. Gating strategy as in Hart et al. (20).
Sample Size, Data Presentation, and
Statistical Analysis
For animal experiments, sample size calculations for Mtb
challenge studies were based on anticipated magnitude of vaccine
effect as 1 Log10 reduction of CFU, the intragroup variability of
0.5 Log10 and a confidence level of 95%. This necessitated 6 mice
per group but due to protracted nature of experiments seven
were used per group. For immunological evaluation three mice
per group were used and data expressed as arithmetic means ±
standard error. Two in vivo experiments were performed with
similar outcomes with the dataset from one experiment shown in
full in Figures 3–7, and onlyMtb challenge data from the second
experiment shown in the Supplemental Information. For all
experiments based on multiple test groups, One-way ANOVA
was performed followed by Dunnett’s multiple comparison test.
Further details of statistical analyses are described in the relevant
figure legends. All analysis was performed using FlowJo v10,
Microsoft Excel 2010 and GraphPad Prism 7.
RESULTS
Biophysical Characterization and Uptake
Analysis of PS Liposomes
Stability is an important issue to be addressed during the
generation of novel liposome based vaccine formulations in
order to ensure efficient antigen delivery (21). This issue has
been addressed by monitoring the kinetics of the encapsulation
of fluorescently labeled AF488-BSA, used as a model antigen.
The analysis performed by flow cytometry and illustrated in
Figure 1B shows that liposomes with encapsulated AF488-BSA
remain stably fluorescent up to 30 days upon generation and
storage at 4◦C. Then, we encapsulated PS liposomes with
mycobacterial antigens (Ag85B and ESAT-6) and further tested
the physical properties of the novel liposome formulation in
terms of size distribution by a Malverin Zetasizer. Results
shown in Figure 1C indicate that the formulation was largely
homogenous with an average size of the liposomes∼240 nm.
An antigen delivery system should ideally target APC and
promote uptake and processing in dendritic cells (DC). Thus,
we preliminarily determined whether PS liposome formulation,
encapsulated with AF647-BSA, were efficiently internalized
by immature and mature human DC. In order to avoid
the contribution of free antigen, liposome formulations were
dialyzed against a 100 kDa membrane to remove non-
encapsulated antigen. Figure 2A shows that the majority
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FIGURE 2 | Antigen internalization and processing in human DC after delivery by PS liposome. (A) Immature and mature DC cells were exposed to dialyzed PS
liposomes loaded with AF647-BSA to a ratio of 5:1 for 1 h. Analysis was performed by flow cytometry. (B) Immature DC cells were stained with the nucleic acid stain
Hoechst and the acidophilic dye Lysotraker Red and stimulated with PS liposomes loaded withAF647-BSA at the ratio 5:1 for 90min. A representative image from
over many taken by confocal microscopy, is shown. Sample analysis indicated majority of cells positively stained with ∼23% strongly positive for both stains.
(C) Immature DC cells were exposed to PS liposomes loaded with DQ-OVA or to empty liposomes at a ratio of 5:1 for 1 h. Red and green fluorescence was evaluated
by flow cytometry. A representative experiment with cells from one, out of three, healthy donors is shown.
of cells became fluorescent after exposure to the liposome
formulation, suggesting that most of the cells have taken
up the antigen. Moreover, in order to establish whether the
antigen was efficiently processed by APC, iDC were exposed
to PS liposomes loaded with AF488 BSA and analyzed by
confocal microscopy after staining with the acidofilic dye
lysotraker red. Results shown in Figure 2B show co-localization
of liposomal AF488-BSA with acid compartments. Finally,
as acidification of endosomal compartments is a prerequisite
for protease activation and the final antigen degradation,
we encapsulated PS liposomes with DQ-OVA, which is a
fluorogenic substrate for proteases, and monitored fluorescence
emission following liposome internalization in iDC. Figure 2C
shows 75% of cells exhibiting green fluorescence, as a
consequence of proteolytic processing of the protein, and
about 23% of cells displaying green/red double fluorescence,
indicating endosomal accumulation of the processed antigen.
Altogether, these results show that PS/PS liposomes may
efficiently deliver the antigen cargo to DC and favor subsequent
antigen processing.
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FIGURE 3 | Reduced Mtb infection in Lipo-AE immunized mice. Four weeks after the final immunization, mice were challenged with aerosolised Mtb and then 4
weeks later culled and organs harvested for bacterial enumeration. Each point corresponds to log CFU value for the individual animals (n = 7). (A) Schematic
depicting immunization and Mtb infection schedule. (B) CFU in the lungs and spleens. The horizontal bars represent the mean for each group ± SEM. Log
transformed data were analyzed using a 1-way ANOVA and a Dunnett’s multiple comparison test comparing all groups to the BCG control or comparing Lipo-AE with
empty liposomes (Lipo); *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001.
Lipo-AE Enhanced BCG Mediated
Protection Against Mtb
In our Mtb infection experiment, BCG afforded ∼8-fold
reduction in the lung and spleen bacterial load (Figure 3),
at 4 weeks after the aerosol challenge. Boosting BCG with
Lipo-AE imparted additional statistically significant reduction
of the bacterial load in both organs sets. The Mtb challenge
experiment was performed twice and in both instances the Lipo-
AE vaccine candidate conferred additional statistically significant
protection over BCG alone, though in one of the experiments
the non-immunized animals group showed greater than expected
intragroup variability (Supplemental Figure S2).
Lipo-AE Induced Mucosal Antibodies and T
Resident Memory Cells (Trm) in Lungs
To measure mucosal responses induced by the vaccine, antibody
levels post-immunization were assessed in bronchoalveolar
lavage (BAL). BAL collected 3 weeks after final immunization
from animals that received Lipo-AE showed similar levels of
IgG but higher levels of IgA specific to Ag85B (Figure 4A),
compared to BCG immunization alone. No detectable anti-
ESAT-6 antibodies were present in either group (not shown).
Upon observingmucosal antibody responses induced by Lipo-
AE, we investigated for evidence of cellular immunity. We were
particularly interested if there was evidence of T cell resident
memory (Trm) in the lungs and used flow cytometry to quantify
these cells in the lung homogenates. Prior to harvest, the lungs
were perfused to reduce blood contamination. The harvested
lungs were then treated and mechanically disrupted to isolate the
cells, which were stained for Trm phenotype (Figure 4B). The
top and bottom panels represent CD4 and CD8 compartments,
respectively. As depicted in the flow plots the total numbers of
Trm as defined by the phenotype CD44 high/CD62L low were very
low for the BCG immunized animals, and this was true for both
the CD4 and CD8 compartments. In stark contrast, there was
a significant increase in Trm populations in the Lipo-AE group
for both T cell compartments, increasing from 2.04 in the BCG
group to 13.22 in the Lipo-AE groups for CD4+ and from 1.50
to 8.16 for CD8+ T cells, respectively (Figure 4B). Naïve animals
showed only background levels of Trm. Although our analysis
was restricted to total and not antigen-specific Trm in the lungs,
together with the evidence of specific antibodies to Ag85B, it
indicates the presence of amucosal immune response in the lungs
of immunized animals.
Splenic T Cell Proliferation and
Polyfunctional T Cells
We then tested splenocyte proliferation in response to recall
antigens as measured by incorporation of radiolabelled
thymidine. As shown in Figure 5A, splenocytes from Lipo-
AE immunized animals proliferated robustly in response to
Ag85B, with a stimulation index of 22, but only modest level of
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FIGURE 4 | Mucosal antibody responses and lung Trm induced by Lipo-AE. (A) Levels of anti-Ag85B specific BAL IgG and IgA determined by antigen-specific ELISA.
Each bar corresponds to the mean of triplicate samples from 3 animals from each group ± SEM. The set of bars represent 3-fold serial dilutions from the starting neat
sample. Average end point titres are indicated above the bars. (B) Analysis of the lung resident memory T cell populations. Except for the PBS group, animals were
vaccinated with BCG sc and then with Lipo-AE or empty liposomes, both containing PolyIC, as described in Methods. Cells isolated from the lungs of immunized
animals were stained and analyzed by flow cytometry to determine the Trm populations. The gating strategy used was cells -> single cells -> live cells -> CD3+ ->
CD4+/CD8+ -> CD44 high/CD62Llow and the CD69/CD103 double positive Trm presented. Data originated from n = 3 pooled animals and a representative
plot is shown.
proliferation was observed for ESAT-6, with a stimulation index
of 4. Cells from the PBS and BCG groups did not proliferate
in response to any of the stimuli. Since liposomes are thought
to enhance cross priming and elicit CD8+ T cell responses, T
cell proliferation in the CD8+ compartment was additionally
investigated by the measurement of Ki67+ cells. Stimulation
with Ag85B but not ESAT-6 induced high levels of proliferation
in the CD8+ T cell population with most of the proliferating
cells being of the CD62Llow/ CD44High phenotype (Figure 5B).
Furthermore, since Lipo-AE induced T cell proliferation
(Figure 5A), we speculated that T cell-associated cytokines were
also being elicited. To test this, splenocyte culture supernatants
were analyzed with a beads-based multiplex immunoassay. The
analytes tested were IFN-y (Figure 5C), IL-10 (Figure 5D), IL-17
(Figure 5E), and IL-4 (Figure 5F). Stimulation with Ag85B as
a recall antigen induced high levels of all cytokines, reflecting a
mixed T cell response with the production of Th1 (IFN-y), Th2
(IL-4), and a Treg cytokines (IL-10 and IL-17), with the latter
characteristic of Th17 responses. BCG vaccination resulted in
minimal cytokine production in these assays.
Splenocytes from Lipo-AE immunized animals displayed low
level ESAT-6 responses (not shown) but stimulation with Ag85B
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FIGURE 5 | Cellular immune response induced by Lipo-AE. (A) Antigen specific splenocyte and T cell proliferation. Splenocytes harvested from immunized animals
were stimulated with Ag85B (blue) o ESAT-6 (red) as the recall antigens and media alone as the negative control, and proliferative responses were then measured by
radiolabelled thymidine incorporation. Vertical bars represent the stimulation indices (stimulation index = antigen specific radioactive counts per minute/background
radioactive counts per minute). (B) CD8T cell proliferation. Splenocytes were stimulated with the recall antigens and the CD8+ Ki67+ cells identified. The gating
strategy used was cells -> single cells -> live cells -> CD90.2+ -> CD8+ -> KI67+ and CD44/CD62L cells. The bars represent the percent of CD8+ cells that are
Ki67+ and are broken down based on memory marker phenotype. (D,E,F) Cytokine production following antigen recall assay. Splenocyte stimulation culture
supernatants were collected and assayed for cytokine presence by. Legendplex: IFN-y (C), IL-10 (D), IL-17 (E), and IL-4 (F). Bars depict means pg/ml ± SEM, with
*indicating statistically significant values above the background (P < 0.05).
resulted in a significant number of cytokine producing CD4+
(1.77%) and CD8+ (0.45%) T cells (Figures 6A,F). In the CD4+
T cell compartment, 1.63% of those cells produced IFN-γ, 1.17%
IL-2, and 1.76% TNF-α (Figure 6B). Lipo-AE also induced the
highest number of polyfunctional T cells producing three or
more of the measured cytokines simultaneously with 1.13% of
cells in this category (Figure 6C). A large portion of these cells
(1.13%) were triple producers, producing INF-γ, IL-2, and TNF-
α simultaneously, with a further population (0.51%) double
producers of IFN-γ and TNF-α (Figure 6D). Of the cytokine
producing cells, most were triple producers (64%) with 31%
producing two cytokines and 5% producing only one of the
measured cytokines (Figure 6E).
A similar picture was observed in the CD8+ T cell
compartment, where Lipo-AE group splenocytes had the
highest number of cytokine producing cells, with 0.11%
producing IFN-γ and 0.32% producing IL-17A. The highest
number of polyfunctional cells producing 3 or more cytokines
simultaneously was also found in the Lipo-AE group (0.036%).
Stimulation with Ag85B resulted in 0.04% of CD8+ T cells
producing IFN-γ, IL-2, and IL-17A, with high levels of single
cytokine producing cells for IFN-γ, 0.12%, and IL-17A, 0.30%. Of
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FIGURE 6 | Polyfunctional T cell responses induced by Lipo-AE. Splenocytes isolated from immunized animals were stimulated with Ag85B and the production of
IFN-γ, IL-2, IL-17A, and TNF-α measured by intracellular cytokine staining and flow cytometry. (A,F) Proportion of CD4 and CD8 positive cells producing cytokines.
(B,G) Proportion of CD4 and CD8 cells expressing each individual cytokine. (C,H) Proportion of CD4 abd CD8 cells producing at least 3 or 4 cytokines.
(D,I) Polyfunctional CD4 and CD8T cells phenotype by cytokine combinations. (E,J) Frequency of single or multiple cytokine producing CD4 and CD8T cells as a
proportion of all antigen specific cells. Gating strategy was the same as in our recent report (20).
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FIGURE 7 | Analysis of the lung resident memory T cell populations. Except for the PBS group, animals were vaccinated with BCG sc and then received one s.c. and
one i.n. administration of Lipo-AE or empty PS/PS liposomes with PolyIC. Cells isolated from the lungs of immunized animals were stained and analyzed by flow
cytometry to determine the Trm populations. The gating strategy used was cells -> single cells -> live cells -> CD3+ -> CD4+/CD8+ -> CD44 high / CD62Llow and
the CD69/CD103 double positive Trm presented. Data originated from n = 3 pooled animals and a representative plot is shown.
the cytokine producing cells the majority were single producers
(92%) with a small proportion of triple producers (8%).
DISCUSSION
Liposomes have been tested in the context of systemic
immunizations but also as oral vaccine vehicles (22, 23). Despite
their relative instability, liposomes were shown to be robust
enough to survive oral delivery to the intestinal lumen and
enhance the antigen presentation (24). Indeed, our own stability
experiments showed that the liposomes used in this study are
stable for at least 30 days. Subsequent Zetasizer analysis also
demonstrated that the formulation was still homogeneous and
the size of the liposomes remained unchanged at∼200 nm.
The mucosal delivery of liposomes in vivo has been tested
extensively through the oral route (22, 25) and also through
the intranasal route (26). A comparison between the two
routes in terms of ability to induce long term local immune
responses seemed to favor the intranasal route (24). Here we
demonstrate the ability of a novel liposome formulation to
protect againstMtb infection when delivered first subcutaneously
and then intranasally. This vaccine strategy was explored as a
heterologous immunization approach on a BCG background.
In human population, boosting BCG would make use of the
large number of already immunized individuals whilst taking
advantage of protective properties of BCG against severe forms
of childhood TB.
Immunization of mice with BCG reduced the burden of
infection significantly in the lungs and spleens in comparison
to unvaccinated animals in a low dose aerosol challenge model.
This protection afforded by BCG was further increased by
boosting with Lipo-AE and this added protection was found
to be statistically significant in both the lungs and spleens.
Upon observing enhancement of protection conferred by Lipo-
AE the immunological profile induced by the vaccine was
studied. Other pre-clinical studies demonstrated that liposomes
promoted antibody and cell mediated immunity to a wide range
of bacterial, protozoan, and viral antigens as well as tumor
cell antigens, venoms and allergens and even live or attenuated
microbial vaccines (6). With regards to cellular immunity, we
observed that stimulation of splenocytes from vaccinated animals
with a recall antigen induced high levels of IFN-y. IgG and IgA
specific to Ag85B was also detected by ELISA in BAL indicating
the vaccine had also successfully primed the B cells in themucosa.
With the view of elucidating further what immune
mechanisms could be behind the observed protection we
further investigated the cellular profiles induced. A cell
proliferation assay revealed that splenocytes isolated from
Lipo-AE vaccinated animals in culture proliferated in response
to Ag85B and to a lesser extent to ESAT-6. These cells produced
high amounts of IFN-y in response to Ag85B stimulation. IFN-y
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is considered essential for resistance to tuberculosis infection
(27, 28). However, despite IFN-y being required for protection
a number of studies have suggested that other mechanisms may
also be needed for protection (29) and the magnitude of IFN-y
response alone is not a reliable correlate of protection (30, 31).
Splenocytes were also found to produce IL-10, which has an
ambiguous role in TB, with some reports showing that it is
undesirable (32) while other suggesting that it can convert human
DCs into macrophage like cells that have increased antibacterial
activity againstMtb (33). Intriguingly, high levels of IL-17A were
also detected in response to Ag85B and to a lesser extent to ESAT-
6 in splenocyte cultures from Lipo-AE vaccinate animals. Whilst
the role of IL-17 inMtb infection is not clearly defined it has been
reported that its induction after vaccination could be beneficial.
Thus, Khader et al. hypothesized that IL-17 producing CD4+ T
cells occupy the lung after infection and elicit the production of
chemokines that attract IFN-y secreting CD4+ T cells resulting
in better control of infection (34).
Thus, the cytokine profile characterized by high IFN-y
and IL-17A with low levels of IL-10 observed here could be
the key to enhanced protection. IL-10 produced by vaccine-
induced Tregs could limit collateral damage within the lung.
It was suggested that granulomas depended on a balance
of inflammatory and anti-inflammatory cytokines in order to
effectively control bacteria (35). This concept was validated
in the Rhesus macaque model, where sterile granulomas were
associated with a balance of IFN-y/IL-17A and IL-10 in contrast
to the non-sterile granulomas that featured a predominantly
inflammatory response lacking IL-10 (36). Finally, evidence from
T. gondii model of infection has shown that multifunctional IL-
10-producing Th1 cells retain their ability to activate intracellular
killing mechanisms in macrophages, and in fact are superior to
conventional IL-10 negative Th1 cells at inducing macrophage
nitrite (NO) production (37). Given that we observed modest IL-
10 and even lower IL-4 production alongside potent Th1/Th17
responses, we therefore conclude that the vaccine induced a
strong Th1-Th17 response with only modest Th2-Treg activity
and this may have contributed to the protection observed.
The superior immunogenicity of Ag85B over ESAT-6 has
also been observed in other studies where both antigens
were used together (38, 39), Ag85B is known to be one
of the most immunogenic TB antigens whilst ESAT-6 is
weakly immunogenic. Nevertheless, both antigens have been
previously shown to be protective, particularly when used in
combination (38, 39).
Ichihashi et al showed that PS could deliver antigens to
APCs resulting in the stimulation of helper and cytotoxic
T cell responses in vivo (17). In keeping with those
observations, a flow cytometry assay measuring Ki67 expression
indicated that the CD8T cells from the Lipo-AE group
proliferated robustly in response to Ag85B antigen and had a
CD62LLow/CD44High phenotype.
CD4+ T cell responses to aerosol Mtb challenge are
characterized by a delayed recruitment of effector T cells in the
lungs, potentially hampering the host’s response to infection and
permitting the bacteria to establish a persistent infection (40).
The rationale behind the heterologous systemic prime mucosal
boost strategy was to elicit a robust systemic response with a
strong mucosal component to challenge the pathogen on entry.
Recently, tissue-memory resident T (Trm) cells have become
topical in the field. Thus, Perdomo et al demonstrated that
mucosal but not subcutaneous, BCG immunization generates
lung resident memory T cell populations that mediate protection
against TB (41). We established that Lipo-AE given mucosally
could generate Trm, characterized as CD69+CD103+ memory
T cells in the lung parenchyma. These cells were found to belong
to both CD4 and CD8 compartment and are likely to be antigen
specific, though we have no formal evidence of their antigen
specificity as we did not have appropriate MHC tetramers to
confirm this.
In conclusion, boosting BCG with Lipo-AE mediated
enhanced immunity and protection over that afforded by BCG
alone. This vaccine delivery platform is well-suited for TB but
the liposomal system can be adapted to suit other diseases and
recently the first ever liposomes-adjuvanted vaccine was licensed
indicated for malaria (42, 43), while a therapeutic vaccine
candidate RUTI formulated in liposomes is currently in clinical
trials (44). This underscores the potential of liposome technology
as an attractive vaccine delivery system.
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